Compare AUBN & AARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AUBN | AARD |
|---|---|---|
| Founded | 1907 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 92.5M | 97.4M |
| IPO Year | 1996 | 2025 |
| Metric | AUBN | AARD |
|---|---|---|
| Price | $25.50 | $1.23 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $7.50 |
| AVG Volume (30 Days) | 2.4K | ★ 1.2M |
| Earning Date | 10-27-2026 | 11-16-2026 |
| Dividend Yield | ★ 4.19% | N/A |
| EPS Growth | 13.66 | ★ 43.11 |
| EPS | ★ 1.29 | N/A |
| Revenue | ★ $619,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $19.96 | ★ N/A |
| Revenue Growth | ★ 0.81 | N/A |
| 52 Week Low | $21.01 | $0.93 |
| 52 Week High | $28.88 | $16.60 |
| Indicator | AUBN | AARD |
|---|---|---|
| Relative Strength Index (RSI) | 40.13 | 23.87 |
| Support Level | $24.17 | $0.93 |
| Resistance Level | $25.71 | $5.88 |
| Average True Range (ATR) | 0.46 | 0.44 |
| MACD | -0.13 | -0.20 |
| Stochastic Oscillator | 58.33 | 9.42 |
Auburn National Bancorp Inc is a bank holding company registered with the Board of Governors of the Federal Reserve System (the Federal Reserve). As a bank holding company, the Company may diversify into a broader range of financial services and other business activities than are currently permitted to the Bank under applicable laws and regulations. The holding company structure also provides greater financial and operating flexibility than is presently permitted to the Bank. The Company's business is conducted through the Bank and its subsidiaries. Although it has no immediate plansto conduct any other business, the Company may engage directly or indirectly in several activities closely related to banking permitted by the Federal Reserve.
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.